On April 24, 2024 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, reported that about 20 accepted abstracts of clinical data from multiple trials in relation to multiple novel mono-/bi-specific antibodies and antibody-drug-conjugates (ADCs) as well as innovative drugs including TYVYT (sintilimab injection), olverembatinib, taletrectinib (ROS1 TKI) from its oncology pipeline will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S (Press release, Innovent Biologics, APR 24, 2024, View Source [SID1234642306]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are very pleased to present a robust set of clinical data for our next-generation innovative bispecific antibodies and ADC molecules for the first time at the 2024 ASCO (Free ASCO Whitepaper) Annual Meeting. We observed the preliminary efficacy and safety signals for those innovative candidates, underscoring their potential for further development and clinical value. As one of the few biopharmaceutical companies with both the technology platforms and robust pipeline in "IO+ADC" areas, Innovent will continue to make breakthroughs in the field of cancer treatment, and is committed to providing doctors and patients with more innovative, effective and safe treatment options."
Details on the abstracts are listed below:
Abstract Title
Abstract No.
Session Type and Title
Presentation Time (CDT)
Presenter
IBI363 (PD-1/IL-2 bispecific antibody)
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study.
3593
Poster Session
-Gastrointestinal Cancer
-Colorectal and Anal
6/1/2024
1:30 PM
-4:30 PM
Dr. Yiwen Chen
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.
9562
Poster Session
-Melanoma/Skin Cancers
6/1/2024
1:30 PM
-4:30 PM
Dr. Yu Chen
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.
e14593
Online publication
5/23/2024
5:00 PM
Dr. Xueli Bai
IBI389 (anti-CLDN18.2/CD3 bispecific antibody)
Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.
2519
Rapid Oral Abstract
-Developmental Therapeutics
-Immunotherapy
6/2/2024
11:30AM
-1:00 PM
Dr. Li Zheng
Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.
4011
Clinical Science Symposium（Oral）-Building Novel Antibody-Based Approaches in Gastrointestinal Cancers
6/2/2024
4:30 PM
-6:00 PM
Dr. Jihui Hao
IBI343(anti-CLDN18.2 ADC)
Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study.
3037
Poster Session
-Developmental Therapeutics
-Molecularly Targeted Agents and Tumor Biology
6/1/2024
9:00 AM
-12:00 PM
Dr. Xianjun Yu
IBI310 (anti-CTLA-4 antibody)
Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.
3505
Oral Abstract Session
-Gastrointestinal Cancer
-Colorectal and Anal
6/2/2024
8:00 AM
-11:00 AM
Dr. Rui-Hua Xu
Taletrectinib (ROS1 TKI)
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.
8520
Rapid Oral Abstract
-Lung Cancer
-Non-Small Cell Metastatic
6/1/2024
4:30PM
-6:00 PM
Dr. Wei Li
IBI110 (anti-LAG-3 antibody)
Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study.
11559
Poster Session
-Sarcoma
6/1/2024
1:30 PM
-4:30 PM
Dr. Jiayong Liu
TYVYT(sintilimab)[1]
Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.
5512
Rapid Oral Abstract
-Gynecologic Cancer
6/1/2024
8:00 AM
-9:30 AM
Dr. Jihong Liu
Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: single-arm, phase II trial.
6011
Clinical Science Symposium (Oral) -making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer
6/3/2024
3:00 PM
-4:00 PM
Dr. Ming Song and Dr. Shida Yan
Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and dedifferentiated liposarcoma (DDLPS): A single-arm phase 2 trial.
11505
Oral Abstract Session
-Sarcoma
6/3/2024
3:00 PM
-6:00 PM
Dr. Zhiguo Luo
Updated survival results of BBCAPX-II: sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.
3563
Poster Session
-Colorectal and Anal
6/1/2024
1:30 PM
-4:30 PM
Dr. Ying Yuan
Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).
4037
Poster Session
-Gastrointestinal Cancer
-Gastroesophageal, Pancreatic, and Hepatobiliary
6/1/2024
1:30 PM
-4:30 PM
Dr. Zhichao Jiang
Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).
4523
Poster Session
-Genitourinary Cancer
-Kidney and Bladder
6/2/2024
9:00 AM
-12:00 AM
Dr. Hao Zeng
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.
4544
Poster Session
-Genitourinary Cancer
-Kidney and Bladder
6/2/2024
9:00 AM
-12:00 AM
Dr. Pei Dong
Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.
5619
Poster Session
-Gynecologic Cancer
6/3/2024
9:00 AM
-12:00 AM
Dr. Xiaohua Wu
Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer
.
8048
Poster Session
-Lung Cancer
-Non-Small Cell Local
-Regional/Small Cell/Other Thoracic Cancers
6/3/2024
1:30 PM
-4:30 PM
Dr.Fuming Qiu
Olverembatinib
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma
11502
Oral Abstract Session
-Sarcoma
6/3/2024
3:00 PM
-6:00 PM
Dr. Haibo Qiu